Autopsy report · NCT03721679
Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1
Cause of deathFunding or business
“Recruiting target patients is intermittent making it impracticable to enroll the required study sample. The administrative responsibilities have been met with extraordinary challenges. Current funding does not match the incurring costs.”
Life of this trial
- Ran for about 2 years 4 months before it stopped.
- 7 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Oncovir, Inc.
- Sponsor type
- Industry
- Conditions
- Solid Cancer
- Interventions
- Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months
- Participants
- 7
- Sites
- 3
- Countries
- United States
Trials that died the same way
- Preventing Tobacco Relapse With Omega-3s Trial
“Difficulty in recruiting patients given a 1 year funding period” - Change in Brain Perfusion During Induction of General Anesthesia
“Difficulties in recruiting patients” - Effects of Physical Treatment on Postural Stability in Benign Paroxysmal Positional Vertigo (BPPV) Patients
“major difficulties recruiting patients” - Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in Infants
“Difficulty in recruiting patients” - A Comparison of Anaesthetic Methods for Total Knee Replacement Surgery
“A number of issues which impact on the ability to recruit patients to the study”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.